Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.
Before Covid-19 came along investors were looking to several Nash catalysts in 2020, and yesterday Akero delivered on one of these.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's…
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.